委托理财管理制度 第一章 总则 第一条 为加强与规范山东威高血液净化制品股份有限公司（以下简称"公 司"）委托理财业务的管理，有效控制风险，提高投资收益，维护公司利益，依 据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易所 股票上市规则》（以下简称"《股票上市规则》"）、《上海证券交易所上市公 司自律监管指引第 5 号——交易与关联交易》等法律、法规、规范性文件及《山 东威高血液净化制品股份有限公司章程》（以下简称"《公司章程》"）的有关 规定，结合公司的实际情况，特制定本制度。 第二条 本制度所称委托理财是指在国家政策允许的情况下，公司在控制投 资风险的前提下，以提高资金使用效率、增加现金资产收益为原则，委托商业银 行、信托公司等金融机构进行短期风险投资理财的行为，包括银行理财产品、信 托产品、委托贷款、债权投资等产品。 第三条 公司从事委托理财应坚持"规范运作、防范风险、谨慎投资、保值 增值"的原则。 第四条 委托理财的资金必须在保证公司日常运营资金的需要为前提，充分 利用好闲置资金，不得挤占公司正常运营和项目建设资金。 第五条 公司进行委托理财时，应当严格按照本制度规定的决策程序、报 ...

山东威高血液净化制品股份有限公司 审计委员会工作细则 第一章 总 则 第一条 为提高山东威高血液净化制品股份有限公司（以下简称"公司"）治理 水平，规范公司审计委员会的运作，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司 独立董事管理办法》《上海证券交易所股票上市规则》《上市公司治理准则》《上海 证券交易所上市公司自律监管指引第 1 号——规范运作》《山东威高血液净化制品股 份有限公司章程》（以下简称"《公司章程》"）及其他有关规定，结合公司实际情 况制订本细则。 第二条 董事会审计委员会是董事会下设的专门委员会，审计委员会对董事会负 责，依照《公司章程》和董事会授权履行职责，审计委员会的提案应当提交董事会审 议决定。 第九条 审计委员会任期与董事会一致，委员任期届满，连选可以连任。期间如 第三条 审计委员会成员应当勤勉尽责，切实有效地监督、评估公司内外部审计 工作，促进公司建立有效的内部控制并提供真实、准确、完整的财务报告。 第四条 公司应当为审计委员会提供必要的工作条件，证券事务部承担审计委员 会的工作联络、会议组织、材料准备和档案 ...

山东威高血液净化制品股份有限公司 控股子公司管理制度 第一章 总则 第一条 为加强山东威高血液净化制品股份有限公司（以下简称"公司"）对控股 子公司（以下简称"子公司"）的管理，确保子公司规范、高效、有序运作，促进子 公司健康发展，提高公司整体资产运营质量，维护公司和投资者的合法权益，根据《中 华人民共和国公司法》《中华人民共和国证券法》《企业内部控制基本规范》《上海 证券交易所股票上市规则》等法律、法规、规章以及《公司章程》的相关规定，结合 公司实际情况，制订本制度。 第二条 本制度所称子公司系指公司直接或间接持有其百分之五十以上的股权比 例，或持股比例虽未超过百分之五十，但能够决定其董事会半数以上成员的组成，或 者通过协议或其他安排能够对其实际控制（即纳入公司合并会计报表的子公司）。 第三条 公司与子公司之间是平等的法人关系。公司以其持有的股权，依法对子公 司享有资产收益、参与重大决策、选择管理层及股权处置等股东权利，并负有对子公 司进行指导、监督和提供相关协助服务的义务。 第四条 子公司依法享有法人财产权，以其法人财产自主经营，自负盈亏，对公司 和其他出资者投入的资本承担保值增值的责任。 第五条 公司对 ...

威高血净公告，2025年上半年营业收入17.65亿元，同比增长8.52%。净利润2.2亿元，同比增长 10.11%。公司拟向全体股东每10股派发现金红利1.6元（含税），合计拟派发现金红利6582.31万元（含 税），占合并报表中归属于上市公司股东净利润的比例为29.89%。 ...

Group 1 - The stock price of Weigao Blood Purification increased by 0.51% on August 22, with a trading volume of 93.215 million yuan [1] - On the same day, Weigao Blood Purification had a financing purchase amount of 10.6694 million yuan and a financing repayment of 13.3753 million yuan, resulting in a net financing buy of -2.7058 million yuan [1] - As of August 22, the total balance of margin trading for Weigao Blood Purification was 94.475 million yuan, which accounts for 6.28% of its circulating market value [1] Group 2 - As of May 19, the number of shareholders of Weigao Blood Purification reached 59,800, an increase of 331,866.67% compared to the previous period [2] - For the first quarter of 2025, Weigao Blood Purification reported an operating income of 896 million yuan, representing a year-on-year growth of 6.44% [2] - The net profit attributable to the parent company for the same period was 112 million yuan, showing a year-on-year increase of 7.91% [2] Group 3 - Weigao Blood Purification, established on December 27, 2004, is located in Weihai Torch High-tech Industrial Development Zone, Shandong Province [1] - The company's main business involves the research, production, and sales of medical products for blood purification, with the revenue composition being: 50.22% from blood dialysis devices, 17.66% from blood dialysis machines, 13.86% from dialysis tubing, 9.82% from dialysis accessories, 6.31% from peritoneal dialysis fluid, and 2.12% from other products [1]

融资融券余额9718.08万元，较昨日上涨4.26%。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-21 | 397.40万 | 9718.08万 | 6.49% | | 2025-08-20 | 297.10万 | 9320.68万 | 6.13% | | 2025-08-19 | 572.23万 | 9023.58万 | 5.92% | | 2025-08-18 | 316.90万 | 8451.35万 | 5.48% | | 2025-08-15 | -1943.01万 | 8046.44万 | 5.23% | 证券之星消息，8月21日，威高血净（603014）融资买入1632.69万元，融资偿还1235.3万元，融资净买 入397.4万元，融资余额9718.08万元，近3个交易日已连续净买入累计1266.73万元，近20个交易日中有 13个交易日出现融资净买入。 融券方面，当日无融券交易。 小知识 融资融券：目前，个人投资者参与融资融券主要需要具备2个条件：1、从事证券交易至少6个月；2、账 户资产 ...

Core Viewpoint - Weigao Blood Purification's stock closed at 40.02 yuan, down 1.19%, with a rolling PE ratio of 35.98 times and a total market value of 16.464 billion yuan [1] Company Overview - Shandong Weigao Blood Purification Products Co., Ltd. specializes in the R&D, production, and sales of blood purification medical products, including blood dialysis devices, blood dialysis tubing, blood dialysis machines, and peritoneal dialysis solutions [1] - The company holds the largest market share in China for blood dialysis devices at 32.5% and blood dialysis tubing at 32.8% as of 2022 [1] - The company ranks fifth in the domestic market for peritoneal dialysis solutions with a market share of 3.6% [1] Financial Performance - In Q1 2025, the company reported revenue of 896 million yuan, a year-on-year increase of 6.44%, and a net profit of 112 million yuan, up 7.91% [2] - The gross profit margin for the company stands at 40.92% [2] Market Position - The average PE ratio for the medical device industry is 59.49 times, while the median is 40.19 times, placing Weigao Blood Purification at the 70th position in the industry [1][2] - The company has 59,754 shareholders as of May 19, 2025, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Industry Overview - On August 18, the medical device industry experienced a rise of 1.45% with a net outflow of main funds amounting to 820 million yuan [1] - A total of 76 constituent stocks increased in value, while 21 stocks saw a decline [1] Fund Flow Analysis - The stocks with the highest net outflow of main funds included Weigao Blood Products (18.8683 million yuan), Shengxiang Biology (16.752 million yuan), New Industry (16.470 million yuan), Dongfulong (15.4047 million yuan), and Weisi Medical (15.0001 million yuan) [1] Stock Performance - Notable stock performances included: - Furuide (60.19 yuan) with a rise of 0.01% and a net inflow of 146 million yuan, accounting for 11.88% of the main fund [1] - Lepu Medical (18.49 yuan) increased by 7.5% with a net inflow of 121 million yuan, representing 7.97% of the main fund [1] - United Imaging (129.66 yuan) saw a 1.33% increase with a net inflow of 87.19 million yuan, making up 8.77% of the main fund [1] - Sanxin Medical (11.11 yuan) rose by 0.89% with a net inflow of 44.13 million yuan, which is 8.05% of the main fund [1] - Sainuo Medical (41.48 yuan) surged by 19.99% with a net inflow of 36.44 million yuan, accounting for 1.44% of the main fund [1] - Huatai Medical (287.92 yuan) decreased by 3.19% with a net outflow of 32.11 million yuan, representing 6.49% of the main fund [1] - Sanofi Biological (21.02 yuan) increased by 0.82% with a net inflow of 30.33 million yuan, making up 9.88% of the main fund [1] - Mindray Medical (236.65 yuan) saw a slight increase of 0.62% with a net inflow of 875.74 thousand yuan, accounting for 1.49% of the main fund [1] - Aide Biological (24.22 yuan) increased by 1.32% with a net inflow of 239.15 thousand yuan, representing 6.53% of the main fund [1] - Mingde Biological (20.98 yuan) rose by 1.01% with a net inflow of 1717.08 thousand yuan, which is 14.09% of the main fund [1]

Core Viewpoint - The company, Weigao Blood Purification, has a current market capitalization of 16.271 billion yuan and a rolling PE ratio of 35.56, which is below the industry average of 55.76 [1][2] Group 1: Company Overview - Weigao Blood Purification specializes in the research, production, and sales of blood purification medical products, including hemodialysis devices, dialysis tubing, dialysis machines, and peritoneal dialysis solutions [1] - The company holds the largest market share in China for hemodialysis devices at 32.5% and for dialysis tubing at 32.8% as of 2022 [1] - The company ranks fifth in the domestic market for peritoneal dialysis solutions with a market share of 3.6% for its exclusive brand Weigao Tailmao [1] Group 2: Financial Performance - In the first quarter of 2025, the company reported revenue of 896 million yuan, reflecting a year-on-year increase of 6.44% [2] - The net profit for the same period was 112 million yuan, showing a year-on-year growth of 7.91%, with a gross profit margin of 40.92% [2] - The company is held by 50 institutions, with a total holding of 0.73 million shares, valued at 0.00 billion yuan [1]

天眼查商业履历信息显示，山东威高血液净化制品股份有限公司，成立于2004年，位于威海市，是一家 以从事专用设备制造业为主的企业。企业注册资本41139.4066万人民币，实缴资本37025.46万人民币。 公司法定代表人为宋修山。 通过天眼查大数据分析，山东威高血液净化制品股份有限公司共对外投资了13家企业，参与招投标项目 2050次，知识产权方面有商标信息40条，专利信息387条，此外企业还拥有行政许可59个。 来源：金融界 金融界消息 截至2025年8月13日收盘，威高血净（603014）报收于40.94元，下跌0.07%，换手率 11.84%，成交量4.51万手，成交金额1.84亿元。 资金流向方面，今日主力资金净流出1424.54万元，占比成交额7.73%。其中，超大单净流出559.06万 元、占成交额3.03%，大单净流出865.49万元、占成交额4.7%，中单净流出流入358.95万元、占成交额 1.95%，小单净流入1065.60万元、占成交额5.78%。 威高血净最新一期业绩显示，截至2025一季报，公司营业总收入8.96亿元、同比增长6.44%，归属净利 润1.12亿元，同比增长7.91%， ...